Hence, targeting the BER pathway—specifically PARP1 and PARP2—forms the basis for the “synthetic lethality” mechanism that the PARP inhibition strategy utilizes for the treatment of those cancer subsets with HRD [31]. The gene discussed is PARP2; the disease is cancer.